(Q36568856)

15 August 2017

1 reference

title

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma (English)

1 reference

15 August 2017

Jonathan W Friedberg

1

1 reference

15 August 2017

Arnold S Freedman

series ordinal

2

1 reference

15 August 2017

publication date

1 July 2006

1 reference

Current Treatment Options in Oncology

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

276-284

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-006-0037-2

15 August 2017

exact match

0 references

cites work

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-006-0037-2

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

21 January 2018

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

1 reference

12 December 2020

Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809

1 reference

12 December 2020

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

12 December 2020

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen

1 reference

12 December 2020

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

12 December 2020

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

1 reference

12 December 2020

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

1 reference

12 December 2020

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a

1 reference

12 December 2020

Epratuzumab: targeting B-cell malignancies through CD22

1 reference

12 December 2020

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

12 December 2020

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

1 reference

12 December 2020

Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected].

1 reference

12 December 2020

Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.

1 reference

12 December 2020

Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example

1 reference

12 December 2020

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

12 December 2020

Interferon-mediated fatigue

1 reference

12 December 2020

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

12 December 2020

The curious case of the baffling biological

1 reference

12 December 2020

CD20-induced B cell death can bypass mitochondria and caspase activation.

1 reference

12 December 2020

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

1 reference

12 December 2020

Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.

1 reference

12 December 2020

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo

1 reference

12 December 2020

Immunotherapeutic uses of CpG oligodeoxynucleotides

1 reference

12 December 2020

CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens

1 reference

12 December 2020

Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy

1 reference

12 December 2020

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

10.1007/S11864-006-0037-2

Identifiers

DOI

1 reference

15 August 2017

1 reference